RhumbLine Advisers’s Pacira BioSciences PCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.78M Sell
122,915
-4,937
-4% -$110K ﹤0.01% 1685
2025
Q4
$3.31M Sell
127,852
-16,452
-11% -$391K ﹤0.01% 1612
2025
Q3
$3.72M Sell
144,304
-4,951
-3% -$122K ﹤0.01% 1577
2025
Q2
$3.57M Buy
149,255
+4,936
+3% +$124K ﹤0.01% 1590
2025
Q1
$3.59M Sell
144,319
-9,754
-6% -$234K ﹤0.01% 1521
2024
Q4
$2.9M Sell
154,073
-7,195
-4% -$126K ﹤0.01% 1699
2024
Q3
$2.43M Buy
161,268
+1,801
+1% +$30.8K ﹤0.01% 1805
2024
Q2
$4.56M Buy
159,467
+9,869
+7% +$281K ﹤0.01% 1447
2024
Q1
$4.37M Buy
149,598
+693
+0.5% +$21.3K ﹤0.01% 1483
2023
Q4
$5.02M Buy
148,905
+7,782
+6% +$228K 0.01% 1406
2023
Q3
$4.33M Buy
141,123
+1,074
+0.8% +$38.7K 0.01% 1446
2023
Q2
$5.61M Buy
140,049
+2,930
+2% +$121K 0.01% 1308
2023
Q1
$5.6M Buy
137,119
+6,576
+5% +$262K 0.01% 1250
2022
Q4
$5.04M Sell
130,543
-379
-0.3% -$18.4K 0.01% 1269
2022
Q3
$6.96M Buy
130,922
+5,287
+4% +$294K 0.01% 1074
2022
Q2
$7.33M Buy
125,635
+8,623
+7% +$565K 0.01% 1063
2022
Q1
$8.93M Buy
117,012
+6,585
+6% +$439K 0.01% 1000
2021
Q4
$6.64M Buy
110,427
+1,130
+1% +$62.3K 0.01% 1205
2021
Q3
$6.12M Sell
109,297
-15,251
-12% -$879K 0.01% 1235
2021
Q2
$7.56M Sell
124,548
-1,447
-1% -$91.6K 0.01% 1179
2021
Q1
$8.83M Buy
125,995
+324
+0.3% +$23.1K 0.01% 1070
2020
Q4
$7.52M Buy
125,671
+6,561
+6% +$384K 0.01% 1109
2020
Q3
$7.16M Sell
119,110
-16,424
-12% -$954K 0.01% 946
2020
Q2
$7.11M Sell
135,534
-5,525
-4% -$231K 0.01% 969
2020
Q1
$4.73M Buy
141,059
+859
+0.6% +$35.7K 0.01% 1057
2019
Q4
$6.35M Buy
140,200
+12,684
+10% +$539K 0.01% 1118
2019
Q3
$4.86M Buy
127,516
+69,364
+119% +$2.77M 0.01% 1202
2019
Q2
$2.53M Buy
58,152
+3,627
+7% +$154K ﹤0.01% 1594
2019
Q1
$2.08M Sell
54,525
-124
-0.2% -$4.84K ﹤0.01% 1684
2018
Q4
$2.35M Buy
54,649
+17,258
+46% +$806K 0.01% 1538
2018
Q3
$1.84M Sell
37,391
-2,506
-6% -$108K ﹤0.01% 1704
2018
Q2
$1.28M Buy
39,897
+1,335
+3% +$46.1K ﹤0.01% 1905
2018
Q1
$1.2M Sell
38,562
-1,030
-3% -$36.7K ﹤0.01% 1857
2017
Q4
$1.81M Sell
39,592
-10,587
-21% -$420K ﹤0.01% 1683
2017
Q3
$1.88M Buy
50,179
+976
+2% +$39.3K ﹤0.01% 1650
2017
Q2
$2.35M Buy
49,203
+1,672
+4% +$77.6K 0.01% 1479
2017
Q1
$2.17M Buy
47,531
+1,771
+4% +$76.5K 0.01% 1502
2016
Q4
$1.48M Buy
45,760
+1,992
+5% +$66.5K ﹤0.01% 1630
2016
Q3
$1.5M Sell
43,768
-948
-2% -$37.1K ﹤0.01% 1589
2016
Q2
$1.51M Buy
44,716
+1,030
+2% +$50.6K ﹤0.01% 1548
2016
Q1
$2.31M Buy
43,686
+1,215
+3% +$71.1K 0.01% 1269
2015
Q4
$3.26M Buy
42,471
+3,160
+8% +$179K 0.01% 1061
2015
Q3
$1.62M Buy
39,311
+833
+2% +$51K 0.01% 1459
2015
Q2
$2.72M Sell
38,478
-1,305
-3% -$103K 0.01% 1211
2015
Q1
$3.54M Buy
39,783
+6,340
+19% +$643K 0.01% 1044
2014
Q4
$2.96M Sell
33,443
-1,565
-4% -$148K 0.01% 1101
2014
Q3
$3.39M Buy
35,008
+140
+0.4% +$13.6K 0.01% 977
2014
Q2
$3.2M Buy
34,868
+4,049
+13% +$308K 0.01% 1062
2014
Q1
$2.16M Sell
30,819
-1,610
-5% -$110K 0.01% 1294
2013
Q4
$1.86M Buy
32,429
+3,190
+11% +$168K 0.01% 1414
2013
Q3
$1.41M Buy
29,239
+459
+2% +$16.7K ﹤0.01% 1550
2013
Q2
$835K Buy
+28,780
New +$833K ﹤0.01% 1888

Other funds holding PCRX